



* Antimicrobial therapy (amoxicillin/clavulanate, 3rd generation cephalosporins or fluoroquinolons) in the last 3 months, hospital admission for more than 48h in the last 3 months, hospital admission in an ESBL-endemic country in the last 6 months, immunosuppression, chronic enteral nutrition, prior recurrent urinary tract disease, life in institutions or nursing home

Hospital-acquired pneumonia
admitted in ICU




* Antimicrobial therapy (amoxicillin/clavulanate, 3rd generation cephalosporins or fluoroquinolons) in the last 3 months or >4 times/year, hospital admission for more than 48h in the last 6 months, immunosuppression, COPD patient with FEV <30%, bronchiectasis




* Antimicrobial therapy (amoxicillin/clavulanate, 3rd generation cephalosporins or fluoroquinolones) in the last 3 months, hospital admission for more than 48h in the last 3 months, hospital admission in an ESBL-endemic country in the last 6 months, immunosuppression, chronic enteral nutrition, prior recurrent urinary tract disease, life in institutions or nursing home

Hospital-acquired pyelonephritis
admitted in ICU



AMC: amoxicillin-clavulanate
PTZ: piperacillin-tazobactam
3GC: 3rd generation cephalosporins
FEP: cefepime



* Antimicrobial therapy (amoxicillin/clavulanate, 3rd generation cephalosporins or fluoroquinolones) in the last 3 months, hospital admission for more than 48h in the last 3 months, hospital admission in an ESBL-endemic country in the last 6 months, immunosuppression, chronic enteral nutrition, prior recurrent urinary tract disease, life in institutions or nursing home